Research

Research
The IMO is at the forefront of research into the latest developments and contributes to the main clinical trials of the day as a member of the EVICR (European Vision Institute Clinical Research Network). The IMO’s leadership and innovative approach are also reflected in a unique and pioneering commitment to translational research, in which ophthalmologists and geneticists work side by side to advance faster in the prevention, diagnosis and treatment of hereditary eye diseases.

Research in IMO

The IMO is at the forefront of research into the latest developments and contributes to the main clinical trials of the day as a member of the EVICR (European Vision Institute Clinical Research Network). The IMO’s leadership and innovative approach are also reflected in a unique and pioneering commitment to translational research, in which ophthalmologists and geneticists work side by side to advance faster in the prevention, diagnosis and treatment of hereditary eye diseases.

Ongoing projects

In the field of clinical research, the objective of projects currently under development is not only to improve the prognosis of patients with certain diseases, but also to offer, for the first time, an effective solution to diseases that are currently untreatable. This is also the ultimate goal of genetic studies, whose aim is to provide in-depth analysis of already known genes and identify new genes related to retinal dystrophies.
Investigación básica

Comprehensive analysis of the ABCA4 gene: characterisation of new pathogenic variants

The vast majority of patients with Stargardt disease, as well as half of recessive cone and rod dystrophy cases, have ABCA4 gene mutations.

Investigación clínica

Spectri

Phase III, multicentre, randomised, double-blind, sham-controlled trial to assess the efficacy and safety of lampalizumab administered by intravitreal injection to patients with geographic atrophy secondary to age-related macular degeneration.

Investigación clínica

Azure

Randomised, active-controlled, parallel group, phase III trial on the efficacy, safety and tolerability of 2 mg aflibercept administered with intyravidial injections using two different regimens of treatment for subjects with neovascular age-related macular degeneration.

Project history

The ophthalmologists, optometrists and nurses who specialise in ocular photography at the IMO carry out several multicentre clinical trials a year, of which the IMO is often the coordinator or main leading centre in Spain. These trials join the pioneering projects carried out by the genetics laboratory.
Investigación clínica

Duoprost

Phase III: Assessment of the efficacy and safety of a fixed combination of unpreserved latanoprost drops and timolol 0.5% (T2347) versus Xalacom® in patients with ocular hypertension or glaucoma.